Welcome, Guest
Username: Password: Remember me
Adult Stem Cell News and Developments other than Cytori
  • Page:
  • 1

TOPIC: SIgnificant Increase in LVEF in BM Autologous N=1

SIgnificant Increase in LVEF in BM Autologous N=1 19 May 2016 10:40 #7063

  • Wall Street Titan
  • Wall Street Titan's Avatar Topic Author
  • Offline
  • Platinum Boarder
  • Platinum Boarder
  • Posts: 901
  • Thank you received: 148
KOOL also suffers from partnership negative autologous model...

RANCHO CORDOVA, Calif., May 19, 2016 (GLOBE NEWSWIRE) -- Cesca Therapeutics Inc. (KOOL), an autologous cell-based regenerative medicine company, today announced publication of data from a pilot study utilizing the company’s innovative technology for treatment of Acute Myocardial Infarction. The report was published in the “International Journal of the Cardiovascular Academy”, currently online*.

Results from the single-patient study titled, “Autologous bone marrow concentrate enriched in progenitor cells - an adjuvant in the treatment of acute myocardial infarction” were obtained using Cesca’s integrated point-of-care technology, Acute Myocardial Infarction Rapid Stem cell Therapy (AMIRST).

The patient was able to return to normal life two weeks after the AMIRST procedure, and the main findings of the study showed a significant improvement in the Left Ventricular Ejection Fraction (LVEF) from 35% at patient’s initial assessment to 60.3% at 24 months post-AMIRST intervention. LVEF is a key indicator of cardiac function, and reduced LVEF levels are considered risk factors for cardiovascular morbidity and mortality. In the publication, the authors note that, “This degree of improvement is considered atypical for a patient having suffered an ST elevated myocardial infarction (STEMI) with an ejection fraction below 40% post reperfusion (stenting).” No major adverse events were observed during the procedure and throughout the 24 month follow-up period. Additionally, data from the study demonstrated that Cesca’s AMIRST integrated technology provided all the components necessary for collection, processing and intracoronary delivery of concentrated stem cells from a patient’s own bone marrow directly into the target artery of the heart. The Company’s patented cell processing technology and proprietary protocol was developed to optimize the quality and quantity of the cells being administered to patients.

Dr. Venkatesh Ponemone, the Study Director and Executive Director of TotipotentRX, a subsidiary of Cesca Therapeutics Inc., commented, “The current standard of care treatment for cardiac regenerative medicine can benefit from improved technology. Cesca’s point-of-care technology overcomes some of the present challenges while also offering a clinical alternative for AMI patients and their physicians. The results from this case encourage our efforts to continue the AMIRST Phase II trial.”

“Cardiovascular morbidity and mortality are a significant economic burden on society, and it is encouraging to see Cesca’s innovative approach with the AMIRST protocol,” added Dr. Vinay Sanghi, MD, Principal Investigator and Associate Director, Interventional Cardiology, Fortis Hospital, Shalimarbagh, India.

*The full report is available online here: www.sciencedirect.com/science/article/pii/S240581811630009

Please Log in or Create an account to join the conversation.

  • Page:
  • 1
Time to create page: 0.075 seconds

Copyright Information

Copyright Fas Kuiters © 2016 young-foxes.com. All Rights Reserved.
This page is made with Joomla CMS and its various templates designed by Fas Kuiters with the excellent Themler tool.



Shared Spreadsheet Links

DOV´s Revised Projections for the Periods 2017 until 2020

Shareble link : HERE

Fas Kuiters Websites